2017 Pediatric Rheumatology Symposium

May 17-20, 2017. Houston, Texas.

View by Number View by Title View Sessions

View by Date

Abstract Number: 136

14-3-3π(eta) Protein in Juvenile Idiopathic Arthritis
Abstract Number: 137

Chromatin Landscapes and Genetic Risk For Juvenile Idiopathic Arthritis
Abstract Number: 138

Modeling Transcriptional Rewiring in Neutrophils through the Course of Treated Juvenile Idiopathic Arthritis
Abstract Number: 139

Dysregulation of miRNA in mononuclear cells of patients with enthesitis related arthritis
Abstract Number: 140

Modular Gene Expression Discrimination of Juvenile Idiopathic Arthritis and Inflammatory Bowel Disease Subphenotypes in Peripheral Blood
Abstract Number: 141

Expression of Siglec-10 on Synovial Fluid CD14dim Monocytes Was Decreased in Juvenile Idiopathic Arthritis Patients
Abstract Number: 142

Neutrophils and monocytes in the early inflammatory cascade of systemic onset Juvenile Idiopathic Arthritis
Abstract Number: 143

Influence of Age and Sex on Collagen-Induced Arthritis
Abstract Number: 144

Linear Discriminant Analysis of Cultured Fibroblast-like Synoviocytes Identifies 6 Candidate Genes Which Predict Extended Course in Juvenile Idiopathic Arthritis
Abstract Number: 145

JAK Inhibition Rescues Novel PSMB8 Mutations
Abstract Number: 146

Age-Related Differences in Neuronal High Mobility Group Box-1 and Resolvin D1 Receptors in Collagen-Induced Arthritis
Abstract Number: 147

Epigenetic and Transcriptomic Profiling of Primary Juvenile Idiopathic Arthritis Patient Cells: Better Understanding of Disease Pathogenesis
Abstract Number: 148

Oral Microbial Profile in Juvenile Idiopathic Arthritis
Abstract Number: 149

Deficiency of Complement C4A or Low Copy Number of Total C4 Genes, HLA-DRB1*15 and HLA-DRB1*03 Are Strong Genetic Risk Factors for Pediatric SLE of European Descent
Abstract Number: 150

Childhood-onset Takayasu Arteritis Associated with Mutations in CBL

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].